Engineering the perfect (bacterial) cancer therapy
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Bacterial therapies possess many unique mechanisms for treating cancer that are unachievable with standard methods. Bacteria can specifically target tumours, actively penetrate tissue, are easily detected and can controllably induce cytotoxicity. Over the past decade, Salmonella, Clostridium and other genera have been shown to control tumour growth and promote survival in animal models. In this Innovation article I propose that synthetic biology techniques can be used to solve many of the key challenges that are associated with bacterial therapies, such as toxicity, stability and efficiency, and can be used to tune their beneficial features, allowing the engineering of 'perfect' cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in certain cases, injection of intratumoral bacteria or their antigens may conversely provide immunostimulatory effects, as demonstrated by Coley’s toxins and recent developments in bacterial cancer therapy (5, 105, 106).”
From The microbiome and human cancer (2021) · cites this paper as [105]
In the citing paper
“BCT is re-gaining attention through synthetic biology techniques that programmatically limit systemic toxicities while enhancing regional antitumor immunity (105, 106).”
From The microbiome and human cancer (2021) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guzman, L. M., Belin, D., Carson, M. J., & Beckwith, J. (1995) · Journal of Bacteriology · doi:10.1128/jb.177.14.4121-4130.1995 · Cited by 4,935
(1989) · PubMed · Cited by 3,343
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×
“Many treatments, including chemotherapy and radiation, are toxic to normal tissue and cannot completely destroy all cancer cell”
BackgroundTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Automated design of synthetic ribosome binding sites to control protein expression
Salis, H. M., Mirsky, E. A., & Voigt, C. A. (2009) · Nature Biotechnology · doi:10.1038/nbt.1568 · Cited by 1,844
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 715
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614 · cited 1×
“This containment is one possible reason that attenuated Salmonella had limited success in reducing tumour growth in human trial”
BackgroundCombination bacteriolytic therapy for the treatment of experimental tumors
Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251543698 · Cited by 563 · cited 1×
“For propulsion and sensing, bacteria have flagella that enable tissue penetratio”
BackgroundCombinatorial engineering of intergenic regions in operons tunes expression of multiple genes
Pfleger, B. F., Pitera, D. J., Smolke, C. D., & Keasling, J. D. (2006) · Nature Biotechnology · doi:10.1038/nbt1226 · Cited by 536 · cited 1×
“, including gene copy number, promoter strength, optimized codons, bacterial metabolism, mRNA secondary structur”
Background
Cited by
Items 201–300 of 905
Salmonella as a Promising Curative Tool against Cancer
Aganja, R. P., Sivasankar, C., Senevirathne, A., & Lee, J. H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102100 · Cited by 62
“At present, the expression of oncogene-silencing RNA and a strategy of incorporating tumor-killing nanoparticles are being developed [30,47].”
BackgroundL-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors
Kim, K., Jeong, J., Lim, D., Hong, Y., Lim, H.-J., Kim, G.-J., Shin, S.-R., Lee, J.-J., Yun, M., Harris, R. A., et al. (2015) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2015.7 · Cited by 61
Escherichia coli Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth
Lian, H., Yang, H., Liu, F., Chen, Y., Tang, S., Ji, W., Tang, J., Liu, Z., Sun, Y., Hu, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20486 · Cited by 65
Bacterial‐Mediated Tumor Therapy: Old Treatment in a New Context
Liu, Y., Niu, L., Li, N., Wang, Y., Liu, M., Su, X., Bao, X., Yin, B., & Shen, S. (2023) · Advanced Science · doi:10.1002/advs.202205641 · Cited by 60
Bacteria synchronized for drug delivery
Zhou, S. (2016) · Nature · doi:10.1038/nature18915 · Cited by 55
Multimodal oncolytic bacteria by coating with tumor cell derived nanoshells
Liu, R., Cao, Z., Wang, L., Wang, X., Lin, S., Wu, F. Q., Pang, Y., & Liu, J. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101537 · Cited by 57
Bacteria-based bioactive materials for cancer imaging and therapy
Chen, Y., Li, Z.-H., Zeng, X., & Zhang, X. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114696 · Cited by 54
Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models
Liang, K., Liu, Q., Li, P., Han, Y., Bian, X., Tang, Y., & Kong, Q. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0021-6 · Cited by 55
Intratumoral bacteria are an important “accomplice” in tumor development and metastasis
Wang, G., He, X., & Wang, Q. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188846 · Cited by 52
Artificial urinary biomarker probes for diagnosis
Xu, C., & Pu, K. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00153-w · Cited by 62
“Bacteria can unimpededly reach tumour sites owing to poor immune surveillance and hypoxia 130,131 , an attribute that is being leveraged to design different active-targeting tumour theranostic systems 132 .”
Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy
Yang, Y., Wang, Y., Zeng, F., Chen, Y., Chen, Z., & Yan, F. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101512 · Cited by 73
In situ biomolecule production by bacteria; a synthetic biology approach to medicine
Bueso, Y. F., Lehouritis, P., & Tangney, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.023 · Cited by 54
Background-suppressed tumor-targeted photoacoustic imaging using bacterial carriers
Gao, R., Liu, F., Liu, W., Zeng, S., Chen, J., Gao, R., Wang, L., Fang, C., Song, L., Sedgwick, A. C., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121982119 · Cited by 51
“coli MG1655 are facultative anaerobic bacteria that have been used as drug delivery systems (42, 43).”
BackgroundMethodRecent advances of aggregation-induced emission materials for fluorescence image-guided surgery
He, W., Zhang, Z., Luo, Y., Kwok, R. T. K., Zhao, Z., & Tang, B. Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121709 · Cited by 54
Salmonella-Mediated Cancer Therapy: Roles and Potential
Nguyen, V. H., & Min, J. (2016) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-016-0415-z · Cited by 53
“In a recent review, bacteria were described as tiny programmable ‘robot factories’ [41], with their flagella as propellers, chemotactic receptors as sensors, and reporter proteins as signal emitter chips that can be used to engineer these bacteria as needed.”
BackgroundFilippou, C., Themistocleous, S., Marangos, G., Panayiotou, Y., Fyrilla, M., Kousparou, C. A., Pana, Z. D., Tsioutis, C., Johnson, E. O., & Yiallouris, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021110 · Cited by 51
“Notably, the cytotoxin-associated gene A ( cagA ) has emerged as a pivotal bacterial protein with profound implications in oncogenesis, primarily by compromising the function of the tumor suppressor protein p53 [102,103].”
BackgroundBioengineered microbes in disease therapy
Paton, A. W., Morona, R., & Paton, J. C. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.05.006 · Cited by 53
Progress of Cell‐Derived Biomimetic Drug Delivery Systems for Cancer Therapy
Lang, T., Yin, Q., & Li, Y. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800053 · Cited by 51
Nanoerythrosome-functionalized biohybrid microswimmers
Buss, N., Yaşa, Ö., Alapan, Y., Akolpoglu, M. B., & Sitti, M. (2020) · APL Bioengineering · doi:10.1063/1.5130670 · Cited by 50
Nanobiohybrids: A Synergistic Integration of Bacteria and Nanomaterials in Cancer Therapy
Chen, Y., Du, M., Yu, J., Rao, L., Chen, X. S., & Chen, Z. (2020) · BIO Integration · doi:10.15212/bioi-2020-0008 · Cited by 51
Impact of the microbiome on cancer progression and response to anti-cancer therapies
Rosean, C. B., Feng, T.-Y., Azar, F. N., & Rutkowski, M. R. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.005 · Cited by 55
“A broader overview of this subject is well-reviewed in (Forbes, 2010).”
BackgroundBacteria-Assisted Transport of Nanomaterials to Improve Drug Delivery in Cancer Therapy
Jiménez‐Jiménez, C., Moreno, V., & Vallet‐Regí, M. (2022) · Nanomaterials · doi:10.3390/nano12020288 · Cited by 65
“When bacteria reach the tumor vasculature, they can extravasated and preferentially accumulate within the hypoxic and nutrient-lacked deep areas of the tumor, thereby colonizing the regions where the necrotic and quiescent cells are placed [102].”
BackgroundChang, M., Dong, C., Huang, H., Ding, L., Feng, W., & Chen, Y. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204791 · Cited by 52
Zhou, T., Wu, J., Tang, H., Liu, D., Jeon, B., Jin, W., Wang, Y., Zheng, Y., Khan, A., Han, H., et al. (2024) · npj Biofilms and Microbiomes · doi:10.1038/s41522-024-00479-8 · Cited by 55
“Due to inhibition of intratumor immune surveillance and availability of necrotic tumor core nutrients, the ability of bacteria to selectively homing tumors promotes novel models of cancer treatment and diagnosis 10,11 .”
Bacterial derivatives mediated drug delivery in cancer therapy: a new generation strategy
Ijaz, M., Hasan, I., Chaudhry, T. H., Huang, R., Zhang, L., Hu, Z., Tan, Q., & Guo, B. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02786-w · Cited by 63
“For instance, the deletion of crucial virulence factor genes has been utilized to attenuate various bacterial species, including Salmonella, Clostridium, Escherichia coli, and Listeria (Table 1) [17–23].”
BackgroundPotent and Tumor specific: Arming Bacteria With Therapeutic Proteins
Dessel, N. V., Swofford, C. A., & Forbes, N. S. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.113 · Cited by 53
Self-citationDual Role of Bacteria in Carcinoma: Stimulation and Inhibition
Al-Hilu, S. A., & Al-Shujairi, W. H. (2020) · International Journal of Microbiology · doi:10.1155/2020/4639761 · Cited by 50
“In the past, living bacteria including Streptococci and Clostridiawere first used by clinicians for cancer therapy and to promote the survival in the animal models, after which genetic engineering was introduced for modifying the bacteria to convert it for bacterial therapies by different mechanisms including native t…”
BackgroundMacpherson, A. M., Barry, S. C., Ricciardelli, C., & Oehler, M. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092967 · Cited by 56
“Preclinical studies with mice have shown that some bacteria, including Salmonella, Escherichia, Clostridium and Bifidobacterium specifically accumulate at the site of tumours in response to chemotactic signals from the TME [256], and may proliferate to numbers that far exceed the number administered due to the distinc…”
BackgroundGenetically engineered bacteria: a new frontier in targeted drug delivery
Fooladi, S., Rabiee, N., & Iravani, S. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01805a · Cited by 53
Zhu, C., Liu, C., Wu, Q., Sheng, T., Zhou, R., Ren, E., Zhang, R., Zhao, Z., Shi, J., Shen, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02028-3 · Cited by 55
Liu, G., Bettegowda, C., Qiao, Y., Staedtke, V., Chan, K. W. Y., Bai, R.-Y., Li, Y., Riggins, G. J., Kinzler, K. W., Bulte, J. W. M., et al. (2013) · Magnetic Resonance in Medicine · doi:10.1002/mrm.24955 · Cited by 51
“For anaerobic bacteria, this selective growth is due to the fact that the only environment sufficiently hypoxic for bacterial germination is within tumors, although other factors may also play a role (2,3,7).”
BackgroundRan, D., Mao, J., Zhan, C., Xie, C., Ruan, H., Man, Y. M., Zhou, J., Lü, W.-L., & Lu, W. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b03518 · Cited by 49
Potential Applications of the Escherichia coli Heat Shock Response in Synthetic Biology
Rodrigues, J. L., & Rodrigues, L. R. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.10.014 · Cited by 45
Escherichiacoli Nissle 1917 as a Novel Microrobot for Tumor-Targeted Imaging and Therapy
Liu, Q., Gai, Y., Chen, Y., Lan, X., & Jiang, D. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081226 · Cited by 50
“However, the following interactions have been identified to contribute to bacteria’s tumor-homing [14,15]: the hypoxic area of solid tumors provides the necessary survival environment for obligate anaerobes and facultative anaerobes, and the necrotic region provides enough nutrients needed for growth.”
BackgroundInfluentialBacteria-based immune therapies for cancer treatment
Howell, L. M., & Forbes, N. S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.006 · Cited by 48
Self-citationHydrogels as promising platforms for engineered living bacteria-mediated therapeutic systems
Yu, S., Sun, H., Li, Y., Wei, S., Xu, J., & Liu, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100435 · Cited by 60
Cancer phototherapy with nano-bacteria biohybrids
Lu, H., Niu, L., Yu, L., Jin, K., Zhang, J., Liu, J., Zhu, X., Wu, Y., & Zhang, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.009 · Cited by 46
In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity
Lin, Z., Meng, F., Ma, Y., Zhang, C., Zhang, Z., Yang, Z., Li, Y., Hou, L., Xu, Y., Liang, X., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.09.007 · Cited by 66
Microbiota in cancer: current understandings and future perspectives
Yao, Y., Zhu, Y., Chen, K., Chen, J., Li, Y., Li, D., & Wei, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02335-3 · Cited by 61
Methods for the development of tumor-targeting bacteria
Hoffman, R. M., & Zhao, M. D. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.916270 · Cited by 46
“Tumor characteristics, which are barriers to standard therapy such as a poor vascularity and hypoxia, are facilitators of bacterial therapy [2].”
BackgroundOptoregulated Protein Release from an Engineered Living Material
Sankaran, S., & del Campo, A. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800312 · Cited by 47
Recent trends and advances in microbe-based drug delivery systems
Shende, P. K., & Basarkar, V. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00291-2 · Cited by 46
Gut microbiota targeted nanomedicine for cancer therapy: Challenges and future considerations
Rajoka, M. S. R., Mehwish, H. M., Xiong, Y., Song, X., Hussain, N., Zhu, Q., & He, Z. (2020) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2020.10.036 · Cited by 47
Hypoxia-responsive nanomaterials for tumor imaging and therapy
Xia, Y., Duan, S., Han, C., Jing, C., Xiao, Z., & Li, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1089446 · Cited by 55
Kuan, Y.-D., & Lee, C. (2015) · Oncotarget · doi:10.18632/oncotarget.6258 · Cited by 49
“This species has several advantages that apply to cancer therapy: because it is flagellated, Salmonella can penetrate deeply into tumor tissue yet viruses, drugs and antibodies cannot [6] and because it is a facultative anaerobe, Salmonella can colonize small metastatic and larger tumors [7].”
Zhang, M., & Forbes, N. S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.014 · Cited by 46
“Salmonella bacteria have the potential to be potent anticancer agents [1, 2].”
BackgroundSelf-citationExterior design: strategies for redecorating the bacterial surface with small molecules
Gautam, S., Gniadek, T. J., Kim, T., & Spiegel, D. A. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.01.012 · Cited by 53
“Since the first examples of “bacterial surface display” in 1986,(4, 5) this methodology has been applied in a variety of settings including environmental remediation,(6) biofuel production,(7) biocatalysis,(7) biosensing,(8) protein library screening,(9) cancer therapeutics,(10) vaccinology,(11-13) and anti-diarrheal…”
BackgroundBio-Nanocarriers for Lung Cancer Management: Befriending the Barriers
Rawal, S. U., & Patel, M. M. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00630-6 · Cited by 51
Reghu, S., & Miyako, E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.1c04037 · Cited by 48
Li, W., Zhang, Z., Liu, J., Wang, B., Pu, G., Li, J., Huang, Y., & Chu, M. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.05.016 · Cited by 49
Hypoxia-targeting bacteria in cancer therapy
Staedtke, V., Sun, N., & Bai, R.-Y. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.03.003 · Cited by 48
Zhu, C., Ji, Z., Ma, J., Ding, Z., Shen, J., & Wang, Q. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070940 · Cited by 45
“With the aid of genetic modifications, the toxicity of bacteria can be reduced and the selective targeting capabilities are greatly enhanced [30].”
BackgroundColorectal cancer treatment using bacteria: focus on molecular mechanisms
Ebrahimzadeh, S., Ahangari, H., Soleimanian, A., Hosseini, K., Ebrahimi, V., Ghasemnejad, T., Soofiyani, S. R., Tarhriz, V., & Eyvazi, S. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02274-3 · Cited by 50
Efficient delivery of antigen to DCs using yeast-derived microparticles
Pan, Y., Li, X., Kang, T., Meng, H., Chen, Z., Yang, L., Wu, Y., Wei, Y., & Gou, M. (2015) · Scientific Reports · doi:10.1038/srep10687 · Cited by 46
Engineering and Visualization of Bacteria for Targeting Infarcted Myocardium
Le, U. N., Kim, H.-S., Kwon, J., Kim, M. Y., Nguyen, V. H., Jiang, S. N., Lee, B.-I., Hong, Y., Shin, M., Rhee, J. H., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.25 · Cited by 46
Precise Thermal Regulation of Engineered Bacteria Secretion for Breast Cancer Treatment In Vivo
Li, L., Pan, H., Pang, G., Lang, H., Shen, Y., Sun, T., Zhang, Y., Liu, J., Chang, J. K., Kang, J. G., et al. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00452 · Cited by 45
Bacteria in cancer therapy: A new generation of weapons
Fan, J., Huang, Y., Li, Y., Muluh, T. A., Fu, S., & Wu, J. (2022) · Cancer Medicine · doi:10.1002/cam4.4799 · Cited by 46
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy
Wang, J., & Maniruzzaman, M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.023 · Cited by 46
Surface Engineering on Bacteria for Tumor Immunotherapy: Strategies and Perspectives
Fu, L., He, Q., Lu, X., Hu, L., Qian, H., & Pei, P. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202405304 · Cited by 44
Swe, P. M., Copp, J. N., Green, L. K., Guise, C. P., Mowday, A. M., Smaill, J. B., Patterson, A. V., & Ackerley, D. F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.002 · Cited by 43
Kocijancic, D., Leschner, S., Felgner, S., Komoll, R., Frahm, M., Pawar, V., & Weiß, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16906 · Cited by 44
“While successful clearance of RenCa may surely require supplementation in an extrinsic form [1, 5, 52, 53], the localized constant stimulation by persistent Salmonella sets it apart from single agent immune therapies externally delivered to the tumor.”
BackgroundZhang, Y., Tan, W., Sultonova, R. D., Nguyen, D.-H., Zheng, J. H., You, S.-H., Rhee, J. H., Kim, S.-Y., Khim, K., Hong, Y., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122135 · Cited by 47
Synthetic biology advancing clinical applications
Folcher, M., & Fussenegger, M. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.06.008 · Cited by 44
Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated Salmonella enterica
Hernández-Luna, M. A., & Luría-Pérez, R. (2018) · Journal of Immunology Research · doi:10.1155/2018/2984247 · Cited by 53
“Over a century and a half after the first reports on bacterial antitumor activity [7, 130], live attenuated Salmonella enterica has been consolidated as an ally in cancer therapy [5, 11, 12, 131].”
BackgroundInfluentialTumor-Targeting Therapy Using Gene-Engineered Anaerobic-Nonpathogenic Bifidobacterium longum
Taniguchi, S., Shimatani, Y., & Fujimori, M. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3515-4_5 · Cited by 41
Engineering the gut microbiota to treat chronic diseases
Dosoky, N. S., Zhang, L., & Davies, S. S. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10771-0 · Cited by 46
“The characteristic tumor-homing properties of Salmonella can be exploited to specifically deliver anti-cancer compounds to tumors and thereby overcome limitations of conventional chemotherapy such as poor tumor selectivity and limited penetrability (Forbes 2010).”
BackgroundEngineering bacteria for cancer immunotherapy
Zalatan, J. G., Petrini, L. F. T., & Geiger, R. (2024) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103061 · Cited by 45
Engineered Microorganisms for Advancing Tumor Therapy
Jia, J., Wang, X., Lin, X., & Zhao, Y. (2024) · Advanced Materials · doi:10.1002/adma.202313389 · Cited by 46
Synthetic mammalian gene circuits for biomedical applications
Ye, H., Aubel, D., & Fussenegger, M. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.10.006 · Cited by 41
Therapy of solid tumors using probiotic Symbioflor-2 - restraints and potential
Kocijancic, D., Felgner, S., Frahm, M., Komoll, R., Iljazović, A., Pawar, V., Rohde, M., Heise, U., Zimmermann, K., Gunzer, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8027 · Cited by 46
Tumour‐targeting bacteria‐based cancer therapies for increased specificity and improved outcome
Felgner, S., Pawar, V., Kocijancic, D., Erhardt, M., & Weiß, S. (2017) · Microbial Biotechnology · doi:10.1111/1751-7915.12787 · Cited by 43
“Such microorganisms exhibit natural tumour-targeting as well as adjuvant abilities (Forbes, 2010).”
BackgroundRapid screening of engineered microbial therapies in a 3D multicellular model
Harimoto, T., Singer, Z. S., Velazquez, O. S., Zhang, J. T., Castro, S., Hinchliffe, T. E., Mather, W., & Danino, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820824116 · Cited by 44
“Notably, many bacteria have been found to selectively colonize tumors in vivo, prompting attempts to engineer bacteria as programmable vehicles to deliver anticancer therapeutics (9).”
BackgroundInfluentialXu, F., He, P., Zeng, C., Li, Y., Das, S. K., Li, B., Yang, H., & Du, Y. (2020) · Oncology Letters · doi:10.3892/ol.2020.12371 · Cited by 44
Swofford, C. A., Jean, A. S., Panteli, J. T., Brentzel, Z. J., & Forbes, N. S. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25184 · Cited by 44
“Bacteria must be able to continuously produce and secrete the protein for an extended period of time to overcome systemic clearance and maintain a lethal concentration within the tumor site (Forbes, 2010).”
BackgroundSelf-citationKawaguchi, K., Igarashi, K., Murakami, T., Kiyuna, T., Zhao, M. D., Zhang, Y., Nelson, S. D., Russell, T. A., Dry, S., Singh, A. S., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1314420 · Cited by 40
“Salmonella typhimurium (VNP20009) has been previously used for effective therapy of a melanoma.(25-31) VNP20009 was attenuated by a lipid A-mutation (msbB), purine auxotrophy (purI) and amino acid auxotrophy.”
MethodQiao, C., Wang, L., Huang, C., Jia, Q., Bao, W., Guo, P., Tan, D., Chen, Z., Shi, C., Rao, Z., et al. (2024) · Advanced Materials · doi:10.1002/adma.202412982 · Cited by 47
Copp, J. N., Williams, E. M., Rich, M. H., Patterson, A. V., Smaill, J. B., & Ackerley, D. F. (2014) · Protein Engineering Design and Selection · doi:10.1093/protein/gzu025 · Cited by 40
“In GDEPT, sensitization is achieved by engineering a tumortargeting viral (Schepelmann and Springer, 2006) or bacterial (Forbes, 2010) vector to encode a gene that encodes a prodrug-activating enzyme, whereas in ADEPT the enzyme is conjugated directly to a tumour-targeting antibody (Knox et al.,…”
BackgroundSun, M., Ye, H., Shi, Q., Xie, J., Xiang, Y., Ling, H., You, S., He, Z., Qin, B. Y., & Sun, J. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100950 · Cited by 43
Culture-Delivery Live Probiotics Dressing for Accelerated Infected Wound Healing
Sun, Y., Liu, M., Tang, X., Zhou, Y., Zhang, J., & Yang, B. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c12845 · Cited by 40
The application of bacteria-nanomaterial hybrids in antitumor therapy
Xiao, S., Mu, M., Feng, C., Pan, S., & Chen, N. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02793-x · Cited by 45
Wu, Y., Liu, B., Yan, Y., Gong, C., Wang, K., Liu, N., Zhu, Y., Li, M., Wang, C., Yang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54883-x · Cited by 52
GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism
Nallar, S. C., & Kalvakolanu, D. V. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.09.001 · Cited by 42
Wu, H., Zhong, D., Zhang, Z., Wu, Y., Li, Y., Mao, H., Luo, K., Kong, D., Gong, Q., & Gu, Z. (2021) · ACS Nano · doi:10.1021/acsnano.0c09594 · Cited by 40
Chen, J., Li, X., Liu, Y., Su, T., Lin, C., Shao, L., Li, L., Li, W., Niu, G., Yu, J., et al. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13894 · Cited by 43
“A live microbe delivers constant concentrations of therapeutics to treat chronic diseases such as cancer, and their unique capabilities are well suited as ideal anticancer agents (Forbes, 2010).”
BackgroundChen, J., Li, T., Liang, J., Huang, Q., Huang, J., Ke, Y., & Sun, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112443 · Cited by 42
Genetic Circuits in Salmonella typhimurium
Prindle, A. B., Selimkhanov, J., Danino, T., Samayoa, P., Goldberg, A. C., Bhatia, S. N., & Hasty, J. (2012) · ACS Synthetic Biology · doi:10.1021/sb300060e · Cited by 43
Synthetic Biology for Therapeutic Applications
Abil, Z., Xiong, X., & Zhao, H. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500392q · Cited by 45
Use of Bacteria in Cancer Therapy
Sarotra, P., & Medhi, B. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42934-2_8 · Cited by 38
Guo, F., Das, J. K., Kobayashi, K. S., Qin, Q., Ficht, T. A., Alaniz, R. C., Song, J. J., & de Figueiredo, P. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003760 · Cited by 46
A rapid screening platform to coculture bacteria within tumor spheroids
Harimoto, T., Deb, D., & Danino, T. (2022) · Nature Protocols · doi:10.1038/s41596-022-00723-5 · Cited by 43
Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
Zhu, C., Wu, Q., Sheng, T., Shi, J., Shen, X., Yu, J., Du, Y., Sun, J., Liang, T., He, K., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.11.002 · Cited by 48
Metabolic Reprogramming Under Microaerobic and Anaerobic Conditions in Bacteria
Shan, Y., Lai, Y., & Yan, A. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5055-5_8 · Cited by 44
Accessing the Inaccessible: Molecular Tools for Bifidobacteria
Sun, Z., Baur, A., Zhurina, D. S., Yuan, J., & Riedel, C. U. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.00551-12 · Cited by 39
“Naturally occurring plasmids are not commonly found in the genus Bifidobacterium, with only 20% of the isolates harboring plasmids (39).”
InfluentialGenetically Engineered Bacterial Protein Nanoparticles for Targeted Cancer Therapy
Yang, H., Jiang, F., Ji, X., Wang, L., Wang, Y., Zhang, L., Tang, Y., Wang, D., Luo, Y., Li, N., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s292432 · Cited by 39
Bioinspired microrobots: Opportunities and challenges in targeted cancer therapy
Singh, A. K., Awasthi, R., & Malviya, R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.042 · Cited by 38
Targeted tumor therapy with L-cyst(e)ine-addicted bacteria-nanodrug biohybrids
Wang, Y., Chen, W., Han, Z., Zhang, S., Ji, P., Zhang, C., Liang, J., & Zhang, X. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.03.012 · Cited by 36
Zhang, Y., Zhang, N., Zhao, M. D., & Hoffman, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.3342 · Cited by 39
“The barriers in tumors for standard therapy such as hypoxia, acidic pH, disorganized vascular architecture, are beneficial for bacteria to target cancer [3].”
BackgroundA novel microfluidic co-culture system for investigation of bacterial cancer targeting
Hong, J. W., Song, S., & Shin, J. H. (2013) · Lab on a Chip · doi:10.1039/c3lc50163a · Cited by 36
Microbiome as an Immunological Modifier
Kumar, M., Singh, P., Murugesan, S., Vétizou, M., McCulloch, J. A., Badger, J. H., Trinchieri, G., & Khodor, S. A. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_27 · Cited by 40
Biomimetic oral targeted delivery of bindarit for immunotherapy of atherosclerosis
Yin, L., Peng, C., Tang, Y., Yuan, Y., Liu, J., Xiang, T., Liu, F., Zhou, X. W., & Li, X. (2020) · Biomaterials Science · doi:10.1039/d0bm00418a · Cited by 39
Metadata
- Authors
- Forbes, N. S.
- Affiliations
- University of Massachusetts Amherst (US)
- Corresponding author
- Forbes, Neil S.
- ORCID
- Forbes, Neil S.
- Venue
- Nature Reviews Cancer
- Published
- 2010-10-14
- Volume
- 10
- Issue
- 11
- Pages
- 785-794
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3756932
- OpenAlex
- W1979507175
- Cited by
- 905
- References
- 141
- Citations by year
- 2026: 76 · 2025: 89 · 2024: 95 · 2023: 76 · 2022: 81 · 2021: 81 · 2020: 69 · 2019: 47 · 2018: 47 · 2017: 46 · 2016: 42 · 2015: 40 · 2014: 45 · 2013: 37 · 2012: 20
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA120825, CA120825)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- bacterial cancer therapy, synthetic biology, Salmonella, Clostridium, tumor targeting, bacterial cytotoxicity, bacterial stability, bacterial toxicity, tumor growth control, cancer immunotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Clostridium, Genetic Engineering, Humans, Neoplasms, Salmonella
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.